Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 31fludarabine 28Whole-Body Irradiation 18Mycophenolic Acid 18venetoclax 14Tacrolimus 14fludarabine phosphate 13Standard of Care 13Specimen Handling 10Practice Guidelines as Topic 10Melphalan 10Busulfan 10Sirolimus 9Thiotepa 8Interviews as Topic 8Azacitidine 8Educational Status 7trametinib 6Surveys and Questionnaires 6Methods 6Mesna 6Biopsy 6thymoglobulin 5Rituximab 5Magnetic Resonance Spectroscopy 5Filgrastim 5Early Intervention, Educational 5Behavior Therapy 5Antilymphocyte Serum 5Peripheral Blood Stem Cell Transplantation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Pegloticase × 1 year × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡